Skip to search formSkip to main contentSkip to account menu

cerivastatin

Known as: cerivastatin [Chemical/Ingredient] 
A synthetic lipid-lowering agent. Cerivastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… 
National Institutes of Health

Related topics

Related topics

13 relations
Cerivastatin sodiumCoronary Artery DiseaseDrug AllergyGemfibrozil

Narrower (2)

CertaKazak

Broader (2)

Hydroxymethylglutaryl-CoA Reductase InhibitorsPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
2006
2006
Statins inhibit hypoxia-induced endothelial proliferation by preventing calcium-induced ROS formation.
Highly Cited
2004
Highly Cited
2004
Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase are commonly used in the clinic to treat… 
Highly Cited
2002
Highly Cited
2002
Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells.
Highly Cited
2002
Highly Cited
2002
Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells.
Review
2002
Review
2002
Controversy surrounding the safety of cerivastatin
The noted myotoxicity and subsequent withdrawal of cerivastatin from the worldwide market in August 2001 has demonstrated that… 
Review
2002
Review
2002
Pharmacological interactions of statins.
Highly Cited
2001
Highly Cited
2001
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.
2001
2001
Lipid‐Lowering Efficacy, Safety, and Costs of a Large‐Scale Therapeutic Statin Formulary Conversion Program
Study Objective. To assess the lipid‐lowering efficacy, safety, and costs of a large‐scale statin formulary conversion program. 
1998
1998
Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
AIMS During the world-wide clinical development of the HMG-CoA reductase inhibitor cerivastatin, pharmacokinetic data have been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)